Dexamethasone and Pregnancy: Maternal Effects
Obstetrical, Endocrine and Metabolic Consequences of Antenatal Dexamethasone Treatment in Pregnant Women at Risk of Congenital Adrenal Hyperplasia
Assistance Publique - Hôpitaux de Paris
35 participants
Sep 30, 2024
OBSERVATIONAL
Conditions
Summary
This study will analyze obstetric, endocrine and metabolic follow-up data in women treated with DEX. It will reveal the prevalence and importance of weight gain, insomnia, edema, stretch marks, arterial hypertension and gestational diabetes, describe pregnancy outcome, and analyze the corticotropic axis during and up to 3 months after pregnancy, with the aim of improving the management of these women and preventing comorbidities. A few studies suggest problems in women treated with DEX during pregnancy. However, all these studies are retrospective, based on self-questionnaires, and have not evaluated all pregnancy outcomes. Moreover, it would appear that a third of women treated with DEX no longer wish to resume the treatment (8). Compliance with treatment is strongly linked to its efficacy. It is therefore important to start investigating the pregnancy outcomes of women treated with DEX. This project is relevant because it has the potential to improve current clinical practice and recommendations related to this treatment, and thus have a direct impact on future patient care. The results of this study will guide us in the management of women presenting an indication for prenatal DEX treatment, and will help to inform the Order of November 15, 2022.
Eligibility
Inclusion Criteria6
- Femme majeure (âge ≥ 18 ans)
- Grossesse avec indication de traitement anténatal par dexaméthasone (DEX) en accord avec le PNDS :
- Mutation sévère du gène CYP21A2 chez chacun des parents
- Fœtus féminin
- Grossesse unique
- Ayant commencé un traitement anténatal par DEX depuis au moins 24h
Exclusion Criteria3
- Contraindication to dexamethasone treatment
- Objection to use of data
- Persons under legal protection (curatorship, guardianship), court-appointed guardians
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06259994